###begin article-title 0
###xml 20 26 <span type="species:ncbi:9986">rabbit</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 344 350 <span type="species:ncbi:9986">rabbit</span>
###xml 375 381 <span type="species:ncbi:9986">rabbit</span>
Mutations in the gene encoding human myocilin (MYOC) have been shown to cause juvenile- and adult-onset glaucoma. In addition, myocilin has been associated with glucocorticoid-induced ocular hypertension and steroid-induced glaucoma. To better understand the role myocilin plays in steroid-induced glaucoma and open-angle glaucoma, we examined rabbit myocilin for use in the rabbit animal model of steroid-induced glaucoma.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 614 623 614 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 19 25 <span type="species:ncbi:9986">rabbit</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 50 56 <span type="species:ncbi:9986">Rabbit</span>
###xml 213 218 <span type="species:ncbi:9606">human</span>
###xml 255 261 <span type="species:ncbi:9986">Rabbit</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
###xml 490 495 <span type="species:ncbi:9606">human</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
###xml 545 551 <span type="species:ncbi:9986">rabbit</span>
###xml 561 564 <span type="species:ncbi:10116">rat</span>
###xml 569 575 <span type="species:ncbi:9913">bovine</span>
###xml 586 592 <span type="species:ncbi:9986">Rabbit</span>
###xml 702 707 <span type="species:ncbi:9606">human</span>
###xml 821 827 <span type="species:ncbi:9986">rabbit</span>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
We have cloned the rabbit ortholog of human MYOC. Rabbit MYOC consists of three exons and an open reading frame encoding a 490 amino acid, 54,882-Da protein, which is 14 amino acids shorter at the N-terminus than human myocilin but 84% identical overall. Rabbit myocilin migrates as a single electrophoretic band, vs. double-banded human myocilin, by SDS-PAGE/immunoblot analysis. We determined that the differential migration exhibited is due to an N-glycosylation site that is present in human (Asn57), monkey and mouse myocilin but absent in rabbit (Ser43), rat and bovine myocilin. Rabbit myocilin is secreted in vitro in trabecular meshwork cell culture and in vivo in aqueous humor. Secretion of human myocilin is shown to be dependent on the signal peptide and independent of the extra 14 amino acids not found in rabbit myocilin. Many of the amino acids in myocilin that are mutated in glaucoma patients are conserved across species.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 19 25 <span type="species:ncbi:9986">rabbit</span>
###xml 56 62 <span type="species:ncbi:9986">rabbit</span>
###xml 132 138 <span type="species:ncbi:9986">rabbit</span>
###xml 196 202 <span type="species:ncbi:9986">rabbit</span>
We have cloned the rabbit MYOC cDNA and determined that rabbit myocilin is secreted but not N-linked glycosylated. Knowledge of the rabbit MYOC cDNA sequence will facilitate future studies in the rabbit animal model examining the role of myocilin in steroid-induced glaucoma and the gain-of-function hypothesis in open-angle glaucoma.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 514 519 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 767 772 767 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
Mutations in MYOC have been shown to be causative for primary open angle glaucoma (POAG) [1-3]. Glucocorticoids have been implicated in ocular hypertension and glaucoma due to increased plasma cortisol levels [4,5] and altered cortisol metabolism [6,7] in POAG patients and from the increased risk of developing POAG in steroid-responsive patients [8,9]. Myocilin has been shown to be upregulated in glucocorticoid-treated human trabecular meshwork (TM) cells [10,11], and there is variable evidence for increased MYOC expression in glaucomatous individuals [12-14]. In addition, glaucoma patients have a higher chance of responding to steroids than non-glaucomatous individuals. However, an extensive study of mutations in the proximal promoter and coding region of MYOC found no sequence polymorphisms associated with steroid responsiveness [15].
###end p 8
###begin p 9
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 588 590 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 611 613 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Myocilin has been shown to be secreted both in human TM cell cultures and in vivo in aqueous humor (AH) [12]. Glaucomatous mutations, however, alter myocilin Triton solubility [16] and prevent myocilin from being secreted [12]. The glycosylation status of myocilin is somewhat controversial. Several groups have shown that myocilin is glycosylated [10,16-21] whereas one group suggests that myocilin is not glycosylated [22]. In our hands, both an N-linked glycosylated (approximately57-kDa) and unglycosylated (approximately55-kDa) form of myocilin is detected in TM cell culture media [17] and aqueous humor [12]. The basis for both secretion and N-linked glycosylation of myocilin is part of the focus of this paper.
###end p 9
###begin p 10
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 0 7 <span type="species:ncbi:9986">Rabbits</span>
###xml 245 251 <span type="species:ncbi:9986">rabbit</span>
###xml 337 343 <span type="species:ncbi:9986">rabbit</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
###xml 499 505 <span type="species:ncbi:9986">rabbit</span>
Rabbits have been successfully used as a model of glucocorticoid-induced ocular hypertension [23-27]. In order to study the association of MYOC gene expression with steroid-induced ocular hypertension, it will be helpful to know the sequence of rabbit myocilin. We report here the cloning, sequence comparison and expression analysis of rabbit MYOC. We show that an N-terminal signal peptide is necessary for myocilin secretion and we identify the N-linked glycosylation site found in human but not rabbit myocilin.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 20 26 <span type="species:ncbi:9986">Rabbit</span>
Characterization of Rabbit MYOC
###end title 12
###begin p 13
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 836 837 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 875 880 875 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 31 37 <span type="species:ncbi:9986">rabbit</span>
###xml 128 134 <span type="species:ncbi:9986">Rabbit</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 281 287 <span type="species:ncbi:9986">Rabbit</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 397 402 <span type="species:ncbi:10090">mouse</span>
###xml 416 422 <span type="species:ncbi:9913">bovine</span>
###xml 492 498 <span type="species:ncbi:9986">rabbit</span>
###xml 662 667 <span type="species:ncbi:9606">human</span>
###xml 680 685 <span type="species:ncbi:10090">mouse</span>
###xml 695 701 <span type="species:ncbi:9986">rabbit</span>
###xml 778 783 <span type="species:ncbi:9606">human</span>
###xml 813 818 <span type="species:ncbi:10090">mouse</span>
###xml 868 874 <span type="species:ncbi:9986">rabbit</span>
We have cloned a 2-kb cDNA for rabbit MYOC that encodes a 490 amino acid, 55-kDa protein with a calculated pI of 5.25 (Fig. 1). Rabbit myocilin amino acid sequence is 84% identical to human myocilin [28] and highly homologous across species (Table 2) with an overall 64% homology. Rabbit myocilin is 14 amino acids shorter at the N-terminus than human myocilin and the same length as monkey [15], mouse [29,30], and bovine [31] myocilin (Fig. 2). As in all myocilin orthologs cloned to date, rabbit myocilin contains a leucine zipper motif (aa 103 to 152) (Fig. 2). A potential peroxisomal targeting signal is encoded on the C-terminus (SKI, aa 488-490). Unlike human, monkey and mouse myoclin, rabbit myocilin does not contain a consensus N-linked glycosylation site (N-X-S/T; human, aa 57-59; monkey, aa 43-45; mouse, aa 43-45) (Fig. 2). The nucleotide sequence for rabbit MYOC reported in this manuscript has been submitted to GenBank (AY191317).
###end p 13
###begin p 14
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Rabbit <italic>MYOC </italic>Sequence</bold>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 68 74 <span type="species:ncbi:9986">rabbit</span>
Rabbit MYOC Sequence. Nucleotide and deduced amino acid sequence of rabbit MYOC cDNA. Open reading frame nucleotides are shown in bold. Encoded amino acids are shown by single letter code and the stop codon is indicated with an asterisk. Numbers to the left indicate nucleotide position. The consensus polyadenylation signal (AATAAA) is underlined.
###end p 14
###begin p 15
###xml 0 31 0 31 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alignment of myocilin orthologs</bold>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 46 52 <span type="species:ncbi:9986">rabbit</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 76 79 <span type="species:ncbi:10116">rat</span>
###xml 85 91 <span type="species:ncbi:9913">bovine</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 395 400 <span type="species:ncbi:9606">human</span>
###xml 705 710 <span type="species:ncbi:9606">Human</span>
###xml 803 809 <span type="species:ncbi:9986">rabbit</span>
###xml 821 826 <span type="species:ncbi:9606">human</span>
###xml 877 882 <span type="species:ncbi:10090">mouse</span>
###xml 894 897 <span type="species:ncbi:10116">rat</span>
###xml 909 915 <span type="species:ncbi:9913">bovine</span>
Alignment of myocilin orthologs. Alignment of rabbit, human, monkey, mouse, rat, and bovine myocilin amino acid sequences. Identical amino acids are shaded and missing amino acids are indicated with a dash. The 14 amino acid deletion in human MYOC plasmid pcDNA3.hMYOC.DeltaN14 is underlined. The putative myocilin signal peptide is boxed. Location of the predicted N-linked glycosylation site (human myocilin Asn57) is indicated with a 'n'. Locations of predicted O-linked glycosylation sites are marked with an 'o'. The leucine zipper motif is marked by dots. Disease-causing mutations identified based on experimental data and statistical arguments with glaucoma family pedigrees and documented in the Human Gene Mutation Database  are indicated with a 'x'. GenBank accession numbers are as follows: rabbit, AY191317; human, NM_000261; monkey, AY190128, AY190129, AY190130; mouse, AF039869; rat, AF093567; bovine, AB027758.
###end p 15
###begin p 16
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 11 16 <span type="species:ncbi:9606">Human</span>
Rabbit and Human MYOC primers used for PCR and Cloning
###end p 16
###begin p 17
* Note: F, forward orientation; R, reverse orientation
###end p 17
###begin p 18
Myocilin ortholog identity comparison
###end p 18
###begin title 19
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 13 19 <span type="species:ncbi:9986">Rabbit</span>
Secretion of Rabbit MYOC
###end title 19
###begin p 20
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 26 32 <span type="species:ncbi:9913">bovine</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 176 181 <span type="species:ncbi:9606">human</span>
###xml 215 218 <span type="species:ncbi:10116">Rat</span>
###xml 299 305 <span type="species:ncbi:9986">rabbit</span>
###xml 365 370 <span type="species:ncbi:9606">human</span>
###xml 406 412 <span type="species:ncbi:9986">rabbit</span>
###xml 463 469 <span type="species:ncbi:9986">rabbit</span>
###xml 518 523 <span type="species:ncbi:9606">human</span>
###xml 583 589 <span type="species:ncbi:9986">rabbit</span>
Rabbit, monkey, mouse and bovine myocilin open reading frames begin at amino acid 15 relative to human myocilin. The function, if any, of the extra N-terminal 14 aa encoded by human myocilin is not presently known. Rat myocilin also contains an extra 13 aa N-terminal sequence [32]. To determine if rabbit myocilin is secreted despite the absence of the additional human-like N-terminal 14 aa, we examined rabbit aqueous humor. We were able to detect myocilin in rabbit aqueous humor (Fig. 3A). This suggests that the human N-terminal 14 aa is dispensible for secretion and that the rabbit myocilin sequence is sufficient to direct secretion.
###end p 20
###begin p 21
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Rabbit <italic>MYOC </italic>expression</bold>
###xml 68 69 68 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 172 173 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 318 322 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 346 350 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 71 77 <span type="species:ncbi:9986">rabbit</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 340 345 <span type="species:ncbi:9606">human</span>
Rabbit MYOC expression. Western immunoblot analysis of myocilin in (A) rabbit, human, and monkey aqueous humor samples treated with (+) or without (-) glycosidases and in (B) GTM66 cells transfected with expression vectors encoding wild-type human MYOC (WT), N-terminal 14 (DeltaN14) or 32 (DeltaN32) aa deleted human MYOC, or N57S mutated human MYOC. I, intracellular myocilin present in the cell lysate; E, extracellular myocilin secreted into the medium. 57/55-kDa myocilin doublet is indicated with arrows.
###end p 21
###begin p 22
###xml 183 184 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 353 355 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 356 358 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 502 504 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 680 682 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 726 728 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 863 868 <span type="species:ncbi:9606">human</span>
###xml 886 891 <span type="species:ncbi:9606">human</span>
Next we created a human myocilin expression construct where the N-terminal 14aa were deleted (pcDNA3.hMYOC.DeltaN14) forcing translation to begin at the second methionine codon (Fig. 2). GTM66 cells were chosen for this study based on their ability to grow and transfect well and are a glaucomatous TM cell line derived from a 92-year-old female donor [11,17]. Transfection of GTM66 cells with the N-terminal deletion mutant resulted in a distribution pattern similar to wild-type human myocilin (Fig. 3B). The fact that we see no discernable difference in the relative mobility between transfected human wild-type myocilin and 14 amino acid amino-terminal deleted myocilin (Fig. 3B) and human vs. monkey myocilin in AH (Fig. 3A) may be due to the use of small format gels or possibly to the usage of the second N-terminal methionine by the cell for synthesizing human myocilin, making human and monkey molecular weights comparable.
###end p 22
###begin p 23
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 777 779 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 424 430 <span type="species:ncbi:9986">rabbit</span>
###xml 445 450 <span type="species:ncbi:9606">human</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 900 906 <span type="species:ncbi:9986">rabbit</span>
Nonetheless, an N-terminal signal peptide is likely necessary for directing synthesis of myocilin, via the ER-Golgi pathway, for secretion outside the cell. To determine what actually constitutes the signal sequence for myocilin, we conducted an analysis of signal peptide cleavage sites using the Center for Biological Sequence Analysis SignalP v1.1 Database . A signal peptide cleavage site was predicted to exist between rabbit aa 18 and 19 (human aa 32 and 33) [33]. We directly tested the importance of the signal peptide in myocilin secretion by replacing the first 32 aa of human myocilin with a single methionine (pcDNA3.hMYOC.DeltaN32). Transfection of GTM66 cells with pcDNA3.hMYOC.DeltaN32 resulted in intracellular but not extracellular myocilin distribution (Fig. 3B). This is the result expected if the signal peptide were necessary for secretion. This suggests that the first 18 aa of rabbit myocilin may function as a signal peptide and are necessary for myocilin secretion.
###end p 23
###begin title 24
Myocilin Glycosylation
###end title 24
###begin p 25
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 360 365 <span type="species:ncbi:9606">Human</span>
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
###xml 489 495 <span type="species:ncbi:9986">rabbit</span>
###xml 497 500 <span type="species:ncbi:10116">rat</span>
###xml 505 511 <span type="species:ncbi:9913">bovine</span>
###xml 714 719 <span type="species:ncbi:9606">human</span>
###xml 731 737 <span type="species:ncbi:9986">rabbit</span>
Human myocilin has been shown to migrate as a 55/57-kDa doublet by SDS-PAGE/immunoblot analysis [10-12,16,17]. The modification accounting for this molecular weight difference is hypothesized to be due to differential glycosylation. N-linked glycosylation sites were predicted using the Center for Biological Sequence Analysis NetNGlyc 1.0 Prediction Server . Human, monkey and mouse myocilin contain a consensus asparagine (N)-linked glycosylation site (NES) near the N-terminus, whereas rabbit, rat and bovine code for SES at this position (Fig. 2). Having a serine present at this position would eliminate N-linked glycosylation and would be predicted to result in a difference in relative gel mobility between human/monkey and rabbit myocilin.
###end p 25
###begin p 26
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 55 61 <span type="species:ncbi:9986">rabbit</span>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 237 243 <span type="species:ncbi:9986">rabbit</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 328 334 <span type="species:ncbi:9986">rabbit</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
To test this hypothesis we analyzed human, monkey, and rabbit AH myocilin side-by-side in SDS-PAGE/immunoblots. The anti-human myocilin antibody 129 used in these studies (generated to human amino acids 156-171[12,17]) cross-reacts with rabbit and monkey myocilin. With human and monkey myocilin we see a clear doublet, whereas rabbit myocilin migrates as a single band with the same relative mobility as the lower band of human and monkey myocilin (Fig. 3A), suggesting that the asparagine vs. serine amino acid difference is responsible for the differential glycosylation.
###end p 26
###begin p 27
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 99 105 <span type="species:ncbi:9986">rabbit</span>
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 442 447 <span type="species:ncbi:9606">human</span>
To directly test this theory, we mutated human myocilin amino acid 57 from Asn to Ser, as found in rabbit myocilin. Media and cell lysate from transfected GTM66 cells contained a single immunoreactive myocilin band that migrated with the same relative mobility as the lower wt myocilin band (Fig. 3B). This suggests that the 55/57-kDa human myocilin doublet is due to differential glycosylation and that the site of N-linked glycosylation on human myocilin is Asn 57.
###end p 27
###begin p 28
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 87 93 <span type="species:ncbi:9986">rabbit</span>
###xml 188 193 <span type="species:ncbi:9606">human</span>
###xml 310 315 <span type="species:ncbi:9606">human</span>
###xml 382 388 <span type="species:ncbi:9986">rabbit</span>
To determine the effects of deglycosylation on myocilin, we treated human, monkey, and rabbit AH with a cocktail of glycosidases (N- and O-linked). Our results show that the upper band of human and monkey myocilin is eliminated whereas the lower band remains unaltered (Fig. 3A). This indicates that the upper human and monkey myocilin band is glycosylated. In addition, the single rabbit myocilin band shifted downward slightly with deglycosylation. This may be due to removal of O-linked glycosylation.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 46 52 <span type="species:ncbi:9986">rabbit</span>
###xml 63 69 <span type="species:ncbi:9986">Rabbit</span>
###xml 447 453 <span type="species:ncbi:9606">humans</span>
###xml 476 482 <span type="species:ncbi:9986">rabbit</span>
###xml 564 569 <span type="species:ncbi:9606">human</span>
###xml 597 602 <span type="species:ncbi:9606">Human</span>
###xml 662 668 <span type="species:ncbi:9986">rabbit</span>
We report the cloning and characterization of rabbit myocilin. Rabbit myocilin is highly similar to the other myocilin orthologs (Table 2) and contains a leucine zipper motif encoded by exon 1 (Fig. 2). This conservation likely reflects the importance of the leucine zipper motif in directing protein-protein interactions [34,35]. Many amino acid mutations encoded in the olfactomedin homology domain of exon 3 that are known to cause glaucoma in humans are also conserved in rabbit myocilin. In fact, all 31 amino acids (34 missense/nonsense mutations total) for human myocilin documented in the Human Gene Mutation Database  to cause glaucoma are conserved in rabbit myocilin (Fig 2).
###end p 30
###begin p 31
###xml 39 48 39 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
Myocilin has been shown to be secreted in vitro and in vivo by several investigators [10-12,20,21,34,36-38]. Secreted proteins typically contain a 16-30 aa signal sequence on their N-terminus which directs the completion of protein synthesis across the ER membrane. A signal peptidase cleaves the signal sequence and the trimmed protein is shuttled through the Golgi for secretion. We demonstrate the functionality of the N-terminal signal peptide in directing myocilin secretion. Deletion of the predicted N-terminal signal peptide results in loss of secretion but not intracellular appearance (Fig. 3B).
###end p 31
###begin p 32
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 809 818 809 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 475 480 <span type="species:ncbi:9606">human</span>
There are conflicting reports on whether myocilin is glycosylated. Differential glycosylation of myocilin has been shown in this report and by others [17,20,21] to account for the appearance of a 55/57-kDa doublet by Western immunoblot analysis. In contrast, Huang et al. [22] report that myocilin is not glycosylated. This discrepancy may be due to technical reasons. Huang et al. did not resolve the 55/57-kDa doublet using their SDS-PAGE system and only detected a 57-kDa human myocilin band, so any deglycosylation (PNGase F, NANase II, and O-Glycosidase) occurring would be difficult to resolve. A positive control was not reported in their deglycosylation experiment, so their conclusion that myocilin is not glycosylated may simply be due to inactive glycosidase. The lack of glycosylation seen in the in vitro canine pancreatic microsomal membrane translation experiment may again be due to poor 55/57-kDa myocilin doublet resolution or the inability of this artificial system to faithfully glycosylate myocilin. However, Caballero et al. was able to detect deglycosylation affects using similar methodology [20].
###end p 32
###begin p 33
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 396 401 <span type="species:ncbi:9606">human</span>
Nguyen et al. [10] identified a 66-kDa band as the glycosylated and major extracellular form of human myocilin and not the upper band in the 55/57-kDa doublet. These authors claim that the lower band of the unglycosylated 55/57-kDa doublet is due to cleavage of the N-terminal 32 amino acid signal peptide. In our hands, we do not see a 66-kDa band on our anti-myocilin Western blots, even using human aqueous humor as a source of myocilin. We provide evidence that the upper band of the 55/57-kDa doublet is the glycosylated form of myocilin (Fig. 3A). Another group has also reported the 66-kDa band using an anti-myocilin antibody different from the Nguyen et al. antibody [14]. The reason for the appearance of this 66-kDa is unclear, but may be due to cross-reaction of the primary or secondary antibody with another protein such as albumin, which has a molecular weight of 65-kDa (GenPept accession # NP_000468). To date, protein sequence data identifying the 66-kDa band as myocilin has not been reported.
###end p 33
###begin p 34
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 358 364 <span type="species:ncbi:9986">rabbit</span>
###xml 558 564 <span type="species:ncbi:9986">rabbit</span>
###xml 601 607 <span type="species:ncbi:9986">rabbit</span>
###xml 666 672 <span type="species:ncbi:9986">rabbit</span>
###xml 677 682 <span type="species:ncbi:9606">human</span>
###xml 747 753 <span type="species:ncbi:9986">rabbit</span>
###xml 873 879 <span type="species:ncbi:9986">rabbit</span>
Human myocilin Asn57 is part of an N-linked glycosylation consensus (NES) and is the only residue on myocilin predicted to be N-glycosylated. We provide both site-directed mutagenesis (Fig. 3B) and deglycosylation (Fig. 3A) evidence that the upper band of the 55/57-kDa human and monkey myocilin doublet is the glycosylated form. The increase in mobility of rabbit myocilin with deglycosylation (Fig. 3A) is likely due to removal of O-linked glycosylation. Analysis of O-linked glycosylation by the CBS NetOGlyc 2.0 Prediction Server  identified two unique (rabbit Thr93 and Thr267) and three common (rabbit Thr66, Thr263, and Ser45) O-linked glycosylation sites in rabbit vs. human/monkey myocilin. The additional O-linked glycosylation sites in rabbit may be responsible for the mobility shift seen in the deglycosylation experiment and the relative diffusiveness of the rabbit myocilin band.
###end p 34
###begin p 35
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 613 619 <span type="species:ncbi:9606">humans</span>
###xml 686 691 <span type="species:ncbi:9606">human</span>
###xml 696 702 <span type="species:ncbi:9986">rabbit</span>
A naturally occuring Asn57Asp polymorphism may be associated with JOAG [39] which, if truly disease-associated, would suggest the functional importance of N-linked glycosylation. N-linked glycosylation is known to confer stability on many extracellular proteins [40]. Myocilin is similar to fibronectin (an extracellular matrix protein) in that both a glycosylated and unglycosylated form is secreted from the cell. The unglycosylated form of fibronectin is more susceptible to proteolytic degradation than the glycosylated form [41]. It will be interesting to determine why two forms of myocilin are secreted in humans and what functionality, if any, N-linked glycosylation imparts on human vs. rabbit myocilin.
###end p 35
###begin p 36
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 372 377 <span type="species:ncbi:10090">mouse</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 599 606 <span type="species:ncbi:9606">patient</span>
###xml 863 868 <span type="species:ncbi:9606">human</span>
It is still unknown how myocilin functions normally and pathophysiologically. However, recent evidence suggests that disease-causing myocilin mutations are gain of function. Disease-causing myocilin mutants are less soluble in Triton [16] and are retained by the cell [12]. Other studies have shown that a truncated form of myocilin does not get secreted [20,21] and that mouse MYOC knockouts are without discernable phenotype [42]. Furthermore, a human hemizygous individual containing an interstitial deletion of chromosome 1, which encodes MYOC, was without evidence of glaucoma [43] and another patient homozygous for a severly truncated form of myocilin had no evidence of glaucoma [44] or other discernable phenotypes. This suggests that MYOC haploinsufficiency is not causative for glaucoma and that myocilin may even be dispensable or redundant in normal human development or only important when ocular stress occurs.
###end p 36
###begin title 37
Conclusions
###end title 37
###begin p 38
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 60 66 <span type="species:ncbi:9986">Rabbit</span>
###xml 107 113 <span type="species:ncbi:9986">rabbit</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
###xml 248 254 <span type="species:ncbi:9986">rabbit</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 408 415 <span type="species:ncbi:9986">Rabbits</span>
Rabbit MYOC encodes a protein highly similar to human MYOC. Rabbit myocilin is secreted and is detected in rabbit aqueous humor. Secretion of myocilin is dependent on an 18 amino acid N-terminal signal peptide. Unlike human and monkey AH myocilin, rabbit myocilin does not undergo canonical N-linked glycosylation due to the substitution of a serine in the analogous human N-linked glycosylation site (N57). Rabbits may provide an in vivo system for modeling some aspects of glaucoma, such as steroid induced ocular hypertension [23-27] and the gain-of-function hypothesis in POAG [42].
###end p 38
###begin title 39
Methods
###end title 39
###begin title 40
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC</italic>
###xml 11 17 <span type="species:ncbi:9986">rabbit</span>
Cloning of rabbit MYOC
###end title 40
###begin p 41
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 29 35 <span type="species:ncbi:9986">rabbit</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 233 239 <span type="species:ncbi:9986">rabbit</span>
###xml 400 406 <span type="species:ncbi:9986">rabbit</span>
###xml 604 610 <span type="species:ncbi:9986">rabbit</span>
Total RNA was extracted from rabbit eye and heart tissue (Pel Freez) using Trizol (Invitrogen). Primers derived from conserved regions of human and mouse MYOC (Table 1, primers Exon1F/Exon1R) were used to amplify a 250-bp section of rabbit MYOC exon 1 (Fig. 1, nts 184-433) by PCR as described [15]. 5' and 3' RACE (Invitrogen) was used to obtain the 5' and 3' cDNA ends. Essentially, two micrograms rabbit total RNA was converted into first strand cDNA with adapter primer and Superscript II reverse transcriptase. Primary and nested 5' and 3' RACE primers were all designed within the 250-bp region of rabbit MYOC exon 1 (Table 1). PCR products were subcloned into TOPOtrade mark TA cloning vectors (Invitrogen) and subjected to cycle sequencing (Division of Molecular Transport, Department of Internal Medicine, University of Texas Southwestern Medical Center).
###end p 41
###begin p 42
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 1146 1151 1122 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 38 44 <span type="species:ncbi:9986">rabbit</span>
###xml 141 147 <span type="species:ncbi:9986">rabbit</span>
###xml 1139 1145 <span type="species:ncbi:9986">rabbit</span>
Due to difficulties in amplifying the rabbit MYOC coding region from cDNA, we pieced together the entire contiguous open-reading frame using rabbit genomic DNA (Clontech; New Zealand White) as a template with a multi-step PCR/ligation process. In the first step, exons 1 and 2 were amplified from genomic DNA with primers P357F/P368R to exon 1 and P355F/P365R to exon 2. Primers P368R and P355F directly abut each other at the exon 1/2 boundary. PCR amplification was performed in a 50 ul volume with the PfuTurbo Hotstart DNA Polymerase system (Stratagene) and included 0.2 mM dNTPs, 100 ng each primer, 2.5 units PfuTurbo DNA polymerase, 100 ng genomic DNA, and 1X cloned Pfu DNA polymerase reaction buffer. Cycling conditions consisted of 2 min at 95degreesC followed by 15 cycles at 95degreesC 30 sec, 60degreesC 30 sec, and 72degreesC 1 min in a Perkin Elmer 9700 thermalcycler. PCR products were restriction digested with BamH1 (exon 1) or Not1 (exon 2), purified from an agarose gel by Qiaquick extraction (Qiagen), and simultaneously subcloned into a BamH1/Not1 digested pcDNA3 (Invitrogen) vector to create a directional clone of rabbit MYOC exons 1 and 2 spliced together (pcDNA3.RbMYOCex1-2). Sequence integrity of the cloned DNA was verified by cycle sequencing and restriction digestion.
###end p 42
###begin p 43
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 383 389 <span type="species:ncbi:9986">rabbit</span>
Exons 1-2 of plasmid pcDNA3.RbMYOCex1-2 was then amplified with primers P357F/P370R and exon 3 was amplified from genomic DNA with primers P356F/P356R. Primers P370R and P356F directly abut each other at the exon 2/3 boundary. PCR was performed as above and PCR products digested with BamH1 (exons 1-2) or Not1 (exon 3) and processed/cloned as above to create a directional clone of rabbit MYOC exons 1-2 and 3 spliced together (pcDNA3.RbMYOCex1-3). Plasmid DNA integrity was confirmed by restriction analysis and cycle sequencing.
###end p 43
###begin title 44
Sequence analysis and comparison
###end title 44
###begin p 45
Alignment of DNA sequence contigs, protein sequences, and plasmid DNA sequence/construction was performed with Vector NTI 7.1 software (Informax).
###end p 45
###begin title 46
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 16 21 <span type="species:ncbi:9606">human</span>
Construction of human MYOC mutants
###end title 46
###begin p 47
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 327 332 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 441 442 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 602 607 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 103 108 <span type="species:ncbi:9606">Human</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
Human MYOC cDNA was cloned into the pcDNA3 (Invitrogen) mammalian expression vector as described [12]. Human myocilin signal sequence deletions were generated by PCR. A 5' PCR primer, with a 5' HindIII site added, was designed to eliminate either the first 42- (P235; DeltaN14) or 96- (P236; DeltaN32) nucleotides of the human MYOC ORF and used in conjunction with a 3' PCR primer (P237) covering the internal Bsu36I restriction site (Table 1). Primer P236 replaced the first 32 amino acid codons with a methionine codon. PCR and processing were as described above with the exception that the 5' human MYOC deletion products were cloned into a HindIII/Bsu36I digested pcDNA3.hMYOC wild-type vector.
###end p 47
###begin p 48
###xml 237 238 237 238 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A</underline>
###xml 260 261 260 261 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 16 21 <span type="species:ncbi:9606">human</span>
Substitution of human myocilin Asn 57 with Ser was accomplished using the QuickChange XL Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions. Primer pair P316F/P316R was designed to replace the Asn57 AAT codon with the Ser AGT codon (Table 1). The entire mutated cDNA was sequence verified and subcloned into a fresh pcDNA3 vector to avoid non-specific Taq DNA polymerase errors. Proper cloning was verified by restriction digestion analysis and sequencing.
###end p 48
###begin title 49
Cell culture and transfection
###end title 49
###begin p 50
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 488 493 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 557 562 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 601 606 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 854 856 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 932 934 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 44 49 <span type="species:ncbi:9606">woman</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 414 420 <span type="species:ncbi:9986">rabbit</span>
###xml 482 487 <span type="species:ncbi:9606">human</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 595 600 <span type="species:ncbi:9606">human</span>
GTM66 cells were derived from a 92-year old woman with glaucoma and were cultured in low glucose DMEM (HyClone Laboratories) with 10% FBS (HyClone Laboratories) and antibiotics (Invitrogen) as described [11,17]. Cells were transfected with Lipofectamine 2000 reagent according to the manufacturers recommendations (Invitrogen). Transfected plasmid DNA included wild-type human MYOC (pcDNA3.hMYOC; [12]), wild-type rabbit MYOC (pcDNA3.RbMYOC.ex1-3), N-terminal 14 amino acid deleted human MYOC (pcDNA3.hMYOC.DeltaN14), N-terminal 32 amino acid deleted human MYOC (pcDNA3.hMYOC.DeltaN32), or N57S human MYOC (pcDNA3.hMYOC.N57S). Cells were switched to serum-free media 24 h post-transfection and media or cell lysates were collected after overnight incubation. Equivalent cell lysate protein amounts (5 mug) were loaded for reduced SDS-PAGE analysis (Fig. 3B). Cell media was not concentrated and was loaded at 16 ul per lane in Fig. 3B.
###end p 50
###begin title 51
Aqueous humor samples
###end title 51
###begin p 52
###xml 452 454 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 510 512 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 186 192 <span type="species:ncbi:9986">Rabbit</span>
###xml 283 290 <span type="species:ncbi:9986">rabbits</span>
###xml 385 390 <span type="species:ncbi:9606">Human</span>
All experimental animals used in this study were treated in compliance with the Association for Research in Vision and Ophthalmology (ARVO) resolution on the use of animals in research. Rabbit aqueous humor samples (135-190 mul) were taken from anesthetized New Zealand Albino (NZA) rabbits and mixed with protease inhibitor cocktail (Complete; Roche) to prevent myocilin degradation. Human aqueous humor samples were obtained as previously described [12]. The equivalent of 4 mul AH was used per lane in Fig. 3A.
###end p 52
###begin title 53
Immunoblot analysis
###end title 53
###begin p 54
Cells were rinsed with PBS and solubilized in a commercial mammalian extraction buffer (M-Pertrade mark; Pierce, Rockford, IL) supplemented with a protease inhibitor cocktail (Complete; Roche) followed by centrifugation at 12,000 x g for 5 min. Protein concentration of the supernatant was determined with Coomassie Plus Protein Assay Reagent (Pierce). Cell extracts were stored at -20degreesC.
###end p 54
###begin p 55
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 320 326 <span type="species:ncbi:9986">rabbit</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 437 443 <span type="species:ncbi:9986">rabbit</span>
Aqueous humor, cell media, and cell extracts were analyzed using pre-cast Criterion 7.5% Tris-HCl polyacrylamide gels (Bio-Rad) and the Bio-Rad electrophoresis system (Bio-Rad). Proteins were electroblotted to Hybond-P PVDF membranes (Amersham Pharmacia Biotech), blocked with gelatin, and probed with affinity purified rabbit anti-human myocilin antibody 129 (AB129; generated to human myocilin amino acids 156-171) [12,17] and an anti-rabbit IgG secondary antibody (Amersham). Immunoreactivity was detected with the ECL Plus detection system (Amersham). Blots were exposed to BioMax MR film (Eastman Kodak) and scanned with a HP ScanJet 7400 c scanner (Hewlett Packard).
###end p 55
###begin title 56
Deglycosylation of aqueous humor myocilin
###end title 56
###begin p 57
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 37 43 <span type="species:ncbi:9986">rabbit</span>
Aqueous humor from human, monkey and rabbit was subjected to deglycosylation with a mixture of N-linked and O-linked glycosidases (PNGase F, sialidase, beta-galactosidase, glucosaminidase and O-glycosidase) using the Enzymatic CarboRelease Kit according to the manufacturers instructions (QA-Bio). AH samples in buffer were boiled for 5 min in the presence of denaturant followed by incubation for 3 hr at 37degreesC with the glycosidase mixture. NuPAGE sample buffer (Invitrogen) was added to stop the reaction, samples were heated for 10 min at 70degreesC and subjected to NuPAGE electrophoresis on 10% NuPAGE gels (Invitrogen). Samples were transferred to PVDF, immunoblotted versus AB129, and developed using ECL Plus.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYOC </italic>
###xml 243 249 <span type="species:ncbi:9986">rabbit</span>
AS carried out the clone isolation and characterization, sequence comparison, plasmid construction, and drafted the manuscript. NJ carried out the cell culture, transfections and immunoblot analyses. RS generated preliminary sequence data for rabbit MYOC and a preliminary manuscript draft. TS provided computer analysis/modeling of myocilin. AL oversaw the work of RS. ES oversaw the work of AL and RS. AC conceived of the study, helped draft the manuscript, and oversaw the work of AS, NJ, and TS.
###end p 59
###begin p 60
All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This work was supported by NIH grant RO1-EY-10564 (ES) and Alcon Research, Ltd. ES is an Investigator of the Howard Hughes Medical Institute.
###end p 62
###begin article-title 63
Identification of a gene that causes primary open angle glaucoma [see comments]
###end article-title 63
###begin article-title 64
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Analysis of myocilin mutations in 1703 glaucoma patients from five different populations
###end article-title 64
###begin article-title 65
Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma
###end article-title 65
###begin article-title 66
Increased plasma free cortisol in ocular hypertension and open angle glaucoma
###end article-title 66
###begin article-title 67
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Aqueous humour and plasma cortisol levels in glaucoma and cataract patients
###end article-title 67
###begin article-title 68
Potentiation of glucocorticoid activity by 5 beta-dihydrocortisol: its role in glaucoma
###end article-title 68
###begin article-title 69
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Decreased 3 alpha-hydroxysteroid dehydrogenase activity in peripheral blood lymphocytes from patients with primary open angle glaucoma
###end article-title 69
###begin article-title 70
The prognosis of corticosteroid-responsive individuals
###end article-title 70
###begin article-title 71
Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma
###end article-title 71
###begin article-title 72
Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells
###end article-title 72
###begin article-title 73
###xml 59 64 <span type="species:ncbi:9606">human</span>
Delayed secondary glucocorticoid responsiveness of MYOC in human trabecular meshwork cells
###end article-title 73
###begin article-title 74
Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor
###end article-title 74
###begin article-title 75
Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork
###end article-title 75
###begin article-title 76
###xml 46 51 <span type="species:ncbi:9606">human</span>
Age independent expression of myocilin in the human trabecular meshwork
###end article-title 76
###begin article-title 77
###xml 62 67 <span type="species:ncbi:9606">human</span>
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension
###end article-title 77
###begin article-title 78
A cellular assay distinguishes normal and mutant TIGR/myocilin protein
###end article-title 78
###begin article-title 79
###xml 54 59 <span type="species:ncbi:9606">human</span>
Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues
###end article-title 79
###begin article-title 80
Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product
###end article-title 80
###begin article-title 81
A trabecular meshwork glucocorticoid response (TIGR) gene mutation affects translocational processing
###end article-title 81
###begin article-title 82
Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain
###end article-title 82
###begin article-title 83
Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma
###end article-title 83
###begin article-title 84
###xml 86 91 <span type="species:ncbi:9606">human</span>
Expression of the TIGR gene in the iris, ciliary body, and trabecular meshwork of the human eye
###end article-title 84
###begin article-title 85
###xml 49 56 <span type="species:ncbi:9986">rabbits</span>
Effects of corticosteroids on ocular dynamics in rabbits
###end article-title 85
###begin article-title 86
###xml 63 69 <span type="species:ncbi:9986">rabbit</span>
Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone
###end article-title 86
###begin article-title 87
###xml 18 25 <span type="species:ncbi:9986">rabbits</span>
Ocular changes in rabbits with corticosteroid-induced ocular hypertension
###end article-title 87
###begin article-title 88
###xml 43 49 <span type="species:ncbi:9986">rabbit</span>
Steroid-induced ocular hypertension in the rabbit: a model using subconjunctival injections
###end article-title 88
###begin article-title 89
###xml 55 61 <span type="species:ncbi:9986">rabbit</span>
Experimental corticosteroid ocular hypertension in the rabbit
###end article-title 89
###begin article-title 90
A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping
###end article-title 90
###begin article-title 91
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Characterization and comparison of the human and mouse GLC1A glaucoma genes
###end article-title 91
###begin article-title 92
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
Characterization of the mouse Myoc/Tigr gene
###end article-title 92
###begin article-title 93
###xml 25 31 <span type="species:ncbi:9913">bovine</span>
Molecular cloning of the bovine MYOC and induction of its expression in trabecular meshwork cells [In Process Citation]
###end article-title 93
###begin article-title 94
###xml 44 47 <span type="species:ncbi:10116">rat</span>
Molecular cloning and expression profile of rat myocilin [In Process Citation]
###end article-title 94
###begin article-title 95
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites
###end article-title 95
###begin article-title 96
Characterization of myocilin-myocilin interactions
###end article-title 96
###begin article-title 97
Protein interactions with myocilin
###end article-title 97
###begin article-title 98
###xml 98 103 <span type="species:ncbi:9606">human</span>
Effects of elevated intraocular pressure on outflow facility and TIGR/MYOC expression in perfused human anterior segments
###end article-title 98
###begin article-title 99
The presence and properties of myocilin in the aqueous humor
###end article-title 99
###begin article-title 100
###xml 17 22 <span type="species:ncbi:9606">human</span>
TIGR/myocilin in human aqueous humor
###end article-title 100
###begin article-title 101
Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma
###end article-title 101
###begin article-title 102
Effect of N-linked glycosylation on glycopeptide and glycoprotein structure
###end article-title 102
###begin article-title 103
Carbohydrates selectively protect a specific domain of fibronectin against proteases
###end article-title 103
###begin article-title 104
###xml 62 67 <span type="species:ncbi:9606">Human</span>
Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function
###end article-title 104
###begin article-title 105
###xml 39 46 <span type="species:ncbi:9606">patient</span>
Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC
###end article-title 105
###begin article-title 106
Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma
###end article-title 106

